Summary
Regeneron Pharmaceuticals, Inc. (REGN) filed an 8-K on February 2, 2016, to report an amendment to its By-Laws, effective January 28, 2016. This amendment implements a majority voting standard for uncontested director elections. Under the new by-laws, a director nominee will be elected if they receive more votes in favor of their election than against it. This change signifies a shift towards greater shareholder influence in board composition, particularly in situations where director nominations are not contested by shareholders. The company noted that director elections would still follow a plurality standard if a shareholder validly nominates a candidate, adhering to advance notice requirements. This development is important for investors as it enhances corporate governance and aligns director accountability more closely with shareholder interests. A majority voting standard in uncontested elections generally means that directors are expected to garner support from a majority of the votes cast, fostering a more responsive board. Investors should note this change as it could influence future board composition and the effectiveness of shareholder engagement on governance matters.
Key Highlights
- 1Regeneron Pharmaceuticals amended its By-Laws to adopt a majority voting standard for uncontested director elections.
- 2The amendment, effective January 28, 2016, requires director nominees to receive more votes cast for than against to be elected.
- 3A plurality voting standard will still apply if a shareholder validly nominates a director candidate.
- 4This change strengthens corporate governance by increasing director accountability to shareholders.
- 5The Board of Directors approved the amendment based on the recommendation of the Corporate Governance and Compliance Committee.
- 6The filing is an 8-K Current Report dated February 2, 2016, reporting an event from January 28, 2016.